Format

Send to

Choose Destination
Nat Biotechnol. 2015 Aug;33(8):842-4. doi: 10.1038/nbt.3280. Epub 2015 Jul 20.

Engineered CHO cells for production of diverse, homogeneous glycoproteins.

Author information

1
1] Center for Glycomics, Cellular and Molecular Medicine and Odontology, Faculty of Health Sciences, University of Copenhagen, Copenhagen N, Denmark. [2] The Novo Nordisk Foundation Center for Biosustainability, The Danish Technical University, Denmark.
2
Center for Glycomics, Cellular and Molecular Medicine and Odontology, Faculty of Health Sciences, University of Copenhagen, Copenhagen N, Denmark.
3
Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
4
1] Center for Glycomics, Cellular and Molecular Medicine and Odontology, Faculty of Health Sciences, University of Copenhagen, Copenhagen N, Denmark. [2] Novo Nordisk A/S, Måløv, Denmark.
5
Novo Nordisk A/S, Måløv, Denmark.

Abstract

Production of glycoprotein therapeutics in Chinese hamster ovary (CHO) cells is limited by the cells' generic capacity for N-glycosylation, and production of glycoproteins with desirable homogeneous glycoforms remains a challenge. We conducted a comprehensive knockout screen of glycosyltransferase genes controlling N-glycosylation in CHO cells and constructed a design matrix that facilitates the generation of desired glycosylation, such as human-like α2,6-linked sialic acid capping. This engineering approach will aid the production of glycoproteins with improved properties and therapeutic potential.

PMID:
26192319
DOI:
10.1038/nbt.3280
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center